Harris Associates’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.86B Sell
4,778,654
-145,857
-3% -$58.2M 2.42% 9
2026
Q2
$1.9B Buy
4,924,511
+127,985
+3% +$47.5M 2.53% 11
2026
Q1
$1.4B Buy
4,796,526
+2,081
+0% +$684K 1.87% 16
2025
Q4
$1.68B Buy
4,794,445
+1,604,821
+50% +$542M 2.12% 16
2025
Q3
$1.03B Buy
3,189,624
+902,059
+39% +$281M 1.65% 21
2025
Q2
$890M Buy
2,287,565
+7,406
+0.3% +$2.98M 1.45% 28
2025
Q1
$992M Buy
2,280,159
+458,875
+25% +$184M 1.67% 24
2024
Q4
$672M Buy
+1,821,284
New +$762M 0.88% 37

Other funds holding ELV

Harris Associates's ELV Position: Q3 2026 in Review

Harris Associates reduced its Elevance Health (ELV) stake by 3% in Q3 2026, selling an estimated $58.2M and leaving 4,778,654 shares worth $1.86B. The position accounts for 2.42% of the portfolio, ranked #9.

Harris Associates first reported a position in ELV in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.9B in Q2 2026. 1,627 funds tracked by Wall St. Rank hold ELV as of Q3 2026.

  • Harris Associates held 4,778,654 shares of Elevance Health worth $1.86B as of Q3 2026.
  • Harris Associates sold 145,857 Elevance Health shares in Q3 2026, an estimated $58.2M.
  • Elevance Health made up 2.42% of Harris Associates's portfolio in Q3 2026, its #9 holding.
  • Harris Associates first reported a position in Elevance Health in Q4 2024 and has held it in 8 quarters since.
  • Harris Associates's Elevance Health position peaked at $1.9B in Q2 2026.
  • 1,627 funds tracked by Wall St. Rank held Elevance Health as of Q3 2026.

Based on Harris Associates's 13F filing for Q3 2026, filed 16 Nov 2026.